Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 12, 2014 (12 years ago)

Gentamicin Injection (Gentamicin Sulfate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Container: Vials may be missing stoppers.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

GENTAMICIN INJECTION, USP, equivalent to 40 mg/mL, Rx only, 20 mL Multiple Dose Vial, Manufactured by APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-010-20

Affected NDC 63323-0010-20

Compare with the code on your package — it is the most precise check available.

Drug: Gentamicin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Gentamicin
Gentamicin Sulfate
NDC 63323-0010
40 mg/mL Injection, Solution
Intramuscular|intravenous
Fresenius Kabi USA, LLC Rx
Recalling firm
Fresenius Kabi USA, LLC
NDC code
63323-010-20
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0290-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Gentamicin recalls

See all
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025
Class II · Moderate risk

Gentamicin Sulfate Cream USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022
Class II · Moderate risk

Gentamicin Sulfate Cream USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 52565-085-15 D-0686-2022

Other recalls by Fresenius Kabi USA, LLC

All 2014 recalls
Class I · High risk

Tyenne (tocilizumab-aazg)

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Ongoing Particulate / foreign matter Fresenius Kabi USA, LLC NDC 65219-594-20 D-0827-2026
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026